NADH-ubiquinone oxidoreductase 16 kDa subunit Antibody

What is NADH-ubiquinone oxidoreductase and why is it important in research?

NADH-ubiquinone oxidoreductase, commonly known as Complex I, is a massive protein complex with a molecular weight of approximately 950,000 Da. It comprises 45-46 different subunits, with seven encoded by mitochondrial DNA and the remainder by nuclear DNA. The complex serves as the entry point for electrons in the mitochondrial respiratory chain, catalyzing electron transfer from NADH via flavin (FMN) and non-heme iron centers . This complex is particularly significant in research because its dysfunction is implicated in numerous pathological conditions, including neurodegenerative disorders like Parkinson's disease, schizophrenia, and diabetes. Additionally, it is sensitive to various environmental toxins and pesticides, making it an important target for toxicological research .

How do researchers verify antibody specificity for Complex I subunits?

Verification of antibody specificity for Complex I subunits typically involves multiple approaches:

• Western blot analysis showing a single band at the expected molecular weight (e.g., 16 kDa for the subunit in question)

• Testing across multiple relevant tissue samples known to express the target (as seen with NDUFA1 antibody testing in mouse heart, kidney, and liver tissues)

• Using positive controls such as fibroblasts, HL-60 cells, or isolated mitochondria

• Employing knockout/knockdown validation to confirm specificity

• Comparing reactivity across species when appropriate (human, mouse, rat)

For example, antibodies like the NDUFA1 antibody (15561-1-AP) undergo rigorous validation through Western blot detection in tissues such as mouse heart, kidney, and liver, with clearly defined molecular weights (observed 7.5 kDa matching the calculated weight) .

What are the optimal conditions for Western blotting with Complex I subunit antibodies?

Optimal Western blotting conditions for Complex I subunit antibodies require careful consideration of several factors:

For example, the NDUFA1 antibody protocol recommends dilutions between 1:500-1:2000 for Western blotting applications . Researchers should optimize these conditions based on their specific experimental setup and target subunit.

How should samples be prepared for immunohistochemistry with Complex I antibodies?

Proper sample preparation for immunohistochemistry with Complex I antibodies includes:

• Fixation: Typically using 4% paraformaldehyde or formalin to preserve tissue architecture while maintaining epitope accessibility

• Antigen retrieval: This is crucial for Complex I antibodies, with recommendations including:

  • TE buffer at pH 9.0 as the primary method

  • Citrate buffer at pH 6.0 as an alternative approach

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody dilution: For Complex I subunit antibodies, dilutions typically range from 1:50-1:500

• Incubation time: Overnight at 4°C for optimal binding

• Detection system: Typically using biotin-streptavidin systems or polymer-based detection methods

These protocols may require optimization depending on the specific tissue being examined and the particular antibody being used. For example, the NDUFA1 antibody has been specifically validated for IHC in mouse liver and heart tissues with recommended dilutions between 1:50-1:500 .

What controls are essential when using Complex I subunit antibodies?

When using Complex I subunit antibodies, the following controls are essential:

• Positive tissue controls: Using tissues known to express high levels of the target (e.g., heart, kidney, and liver tissues for NDUFA1)

• Negative controls:

  • Primary antibody omission

  • Non-specific IgG from the same species as the primary antibody

  • Tissues known not to express the target

• Peptide competition assays: Pre-incubating the antibody with the immunogenic peptide to confirm specificity

• Knockout/knockdown controls: When available, tissues or cells lacking the target protein

• Cross-reactivity controls: Testing for specificity across related proteins

For instance, documentation for Complex I antibodies typically specifies positive controls, such as fibroblasts, HL-60 cells, and tissue mitochondria preparations .

How can Complex I subunit antibodies be used to study neurodegenerative diseases?

Complex I subunit antibodies provide valuable tools for investigating neurodegenerative diseases through several approaches:

• Protein expression analysis: Quantifying changes in Complex I subunit levels in affected tissues (e.g., substantia nigra in Parkinson's disease)

• Post-translational modification studies: Examining oxidative modifications or phosphorylation states that may affect Complex I function

• Protein-protein interaction studies: Identifying altered interactions between Complex I subunits and other proteins

• Subcellular localization: Determining if Complex I assembly or localization is disrupted in disease states

• Histopathological assessment: Evaluating tissue-specific changes in Complex I distribution or abundance

Research with Complex I antibodies has contributed to understanding mitochondrial dysfunction in neurodegenerative conditions, including Parkinson's disease and schizophrenia . These studies help elucidate the molecular mechanisms underlying these disorders and identify potential therapeutic targets.

What approaches can be used to investigate GRIM-19's role in Complex I assembly?

GRIM-19 (Gene associated with Retinoid-Interferon-induced Mortality 19) is essential for proper assembly of Complex I, making it an important research target. Strategies to investigate its role include:

• Co-immunoprecipitation studies: To identify GRIM-19's interaction partners within Complex I

• Knockdown/knockout models: GRIM-19 knockout studies have demonstrated its essential role in Complex I assembly

• Blue Native PAGE: To analyze intact Complex I assembly in the presence/absence of GRIM-19

• Immunofluorescence microscopy: To visualize GRIM-19 co-localization with other Complex I subunits

• Proximity ligation assays: To detect protein-protein interactions between GRIM-19 and other Complex I components

The dual role of GRIM-19 in both Complex I assembly and apoptotic regulation makes it particularly interesting for researchers investigating the links between mitochondrial function and cell death pathways . Studies have shown that GRIM-19 knockout is embryonically lethal, highlighting its essential role in cellular energetics and development .

How can researchers distinguish between assembly defects and expression deficiencies?

Distinguishing between Complex I assembly defects and expression deficiencies requires a multi-faceted approach:

By employing multiple antibodies against different Complex I subunits (including the 16 kDa subunit), researchers can determine whether observed deficiencies result from problems in protein expression, import, or the assembly process itself.

How can Complex I subunit antibodies be used in high-throughput screening?

Complex I subunit antibodies can be adapted for high-throughput screening applications through several methodologies:

• ELISA-based assays: Developing quantitative assays for specific subunits in multiple samples

• Tissue microarrays: Analyzing numerous tissue samples simultaneously using immunohistochemistry

• Automated Western blotting systems: Processing multiple samples with standardized protocols

• Flow cytometry: For cell-based screening when combined with permeabilization protocols

• Protein array platforms: Testing interactions with multiple potential binding partners

These approaches allow researchers to efficiently screen compounds that might affect Complex I expression, assembly, or function. This is particularly valuable when investigating potential therapeutic agents for mitochondrial disorders or when conducting toxicological studies on compounds that might inhibit Complex I.

What are the considerations when investigating post-translational modifications?

When investigating post-translational modifications (PTMs) of Complex I subunits:

• Specific antibodies: Use modification-specific antibodies (phospho, acetyl, ubiquitin, etc.) in conjunction with subunit-specific antibodies

• Sample preparation: Include phosphatase inhibitors, deacetylase inhibitors, or proteasome inhibitors as appropriate

• Enrichment techniques: Consider using phosphopeptide enrichment, immunoprecipitation, or other enrichment methods prior to analysis

• Mass spectrometry validation: Confirm PTMs identified by antibody-based methods with MS analysis

• Functional correlation: Correlate identified PTMs with Complex I activity measurements

Since many Complex I subunits, including potentially the 16 kDa subunit, can undergo various PTMs that affect function, using appropriate antibodies and analytical techniques is crucial for understanding these regulatory mechanisms.

How can researchers integrate antibody-based detection with functional assays?

To comprehensively understand Complex I biology, researchers should integrate antibody-based detection with functional assays through:

• Parallel analysis: Measuring Complex I activity using spectrophotometric assays alongside expression analysis

• Sequential immunocapture: Isolating Complex I using antibodies followed by activity measurements

• In-gel activity assays: Following Blue Native PAGE separation with activity staining and subsequent Western blotting

• Respirometry correlation: Correlating antibody-detected protein levels with oxygen consumption measurements

• Live-cell imaging: Combining immunofluorescence with functional probes (e.g., mitochondrial membrane potential dyes)

This integrated approach allows researchers to correlate structural information (obtained through antibody-based detection) with functional data, providing a more complete understanding of how alterations in Complex I subunits affect mitochondrial function.

How can researchers troubleshoot non-specific binding with Complex I antibodies?

When encountering non-specific binding with Complex I subunit antibodies, researchers should consider:

• Increasing blocking time or concentration: Using 5% BSA or milk for 1-2 hours at room temperature

• Optimizing antibody dilution: Testing a range of dilutions to find the optimal signal-to-noise ratio

• Adjusting washing conditions: Increasing the number or duration of washes with PBS-T

• Using alternative blocking agents: Switching between BSA, milk, or commercial blocking solutions

• Reducing primary antibody incubation time: Shortening from overnight to 2-4 hours

• Pre-absorbing the antibody: Incubating with non-relevant tissue lysate before use

• Testing different detection systems: Switching between chemiluminescence, fluorescence, or colorimetric detection

Each antibody may require specific optimization steps, and researchers should systematically test these variables to achieve optimal specificity and sensitivity.

What are the best storage and handling practices for maintaining antibody activity?

To maintain optimal activity of Complex I subunit antibodies:

For example, the NDUFA1 antibody documentation specifies storage at -20°C for up to one year after shipment, with the buffer containing PBS, 0.02% sodium azide, and 50% glycerol at pH 7.3 .